![]() |
市场调查报告书
商品编码
1373944
功能服务提供者(FSP)的全球市场预测(截至2027年)Functional Service Providers (FSP) Market Research Report Forecast till 2027 |
在研究期间,全球功能服务提供者 (FSP) 市场规模预计将以 7.49% 的复合年增长率健康成长。
该市场受到多种因素的推动,例如研发企业的扩张、临床前试验的增加以及药物改进中 FSP 外包的增加。
不断增加的研发活动,尤其是生物製药和生技公司的研发活动,正在推动全球市场对功能服务提供者 (FSP) 的需求。研究表明,大型生物製药公司对 FSP 的使用每年以超过 13% 的速度成长。
区域考虑
北美市场形成最大市场,2022年市占率约41%。这是由于该地区拥有完善的医疗基础设施、大量的临床前研究以及 IQVIA(美国)、Parexel(美国)和 Labcorp Memination Improvement(美国)等关键参与者。
欧洲市场因技术创新不断增加、医疗消费增加、慢性病盛行率上升而占据第二大市场。据 EMA 称,欧盟成员国在任何特定时间正在进行约 4,000 项临床试验。预计到 2022 年,德国将占据最大的市场份额,而法国将成为欧洲成长最快的市场。
预计2023年至2027年亚太市场发展最快。
该报告研究和分析了全球功能服务提供者(FSP)市场,提供市场动态、区域和细分市场分析、公司概况等。
The Functional Service Providers (FSP) is anticipated to register a healthy CAGR of 7.49% during the review period.
This market is being driven by various elements, including expanding Research and development ventures, the rising number of clinical preliminaries, and the ascent of FSP outsourcing in drug improvement.
Rising Research and development speculations, particularly in the biopharmaceutical and biotechnology businesses, have made a requirement for functional service providers (FSPs) in the worldwide market. Research showed that the utilization of FSPs by enormous biopharmaceutical organizations is developing at a pace of over 13% yearly. These service providers offer staff to biopharmaceutical and biotechnology organizations for their exploration and advancement projects. They give profoundly qualified research partners, information supervisors, concentrate on organizers, clinical screens, and other related staff backing to these organizations.
Moreover, FSPs offer arrangements like preliminary administration, clinical checking, information the executives, factual programming, biostatistics, clinical composition, lifecycle security, and administrative undertakings. The tedious and costly nature of clinical preliminaries and the issues brought about by the high responsibility bring about the rising notoriety of FSPs. These providers save the organization time and lessen functional expenses.
Segment Insights
Segmentation of the global functional service provider market by type includes clinical monitoring, medical publishing, data management, pharmacovigilance, biostatistics/programming, regulatory, and others.
Based on phase, the global functional service provider market has been segmented into clinical trial phase and post-approval phase. Based on applications, the global functional service providers industry has been segmented into biopharmaceutical companies, biotechnology companies, medical device companies, and research centers and hubs. University institutes.
Regional Insights
The North America functional service providers market represented the biggest market with a portion of roughly 41% in 2022, because of the created medical care foundation, countless clinical preliminaries, and the presence of significant central participants in the region like IQVIA (US), Parexel (US), and Labcorp Medication Improvement (US).
Europe functional service supplier market represented the second-biggest market share because of innovation headways, expanding medical care consumption, and expanding predominance of ongoing sicknesses. As per the EMA, around 4,000 clinical preliminaries happen consistently across the European Association (EU) nations. Moreover, the Germany functional service supplier held the biggest market share in 2022, and the France functional service providers is extended be the quickest developing market in the Europe region.
The Asia-Pacific functional service providers market is supposed to be the quickest developing from 2023 to 2027 attributable to high understanding populace, decreased expenses of leading preliminaries, and great administrative arrangements. Also, central members working in the Functional Service Providers (FSP) Market are effectively venturing into Asia-Pacific region. For example, in July 2018, Parexel (US) laid out another auxiliary called Wellbeing Advances in Hong Kong to grow its capacities in the APAC region.
Key Companies in the Functional Service Providers Market are Quanticate International Limited (UK), IQVIA, Inc. (US), BioPoint Inc. (US), Rho, Inc. (US), KPS Life, LLC (US), Parexel International Corporation (US), Laboratory Corporation of America Holdings (US), Wuxi Apptec co., Ltd. (China), Icon Plc (Ireland), and PPD Inc. (US).
TABLE OF CONTENTS